How Acetaminophen Causes Liver Damage and What to Do

Acetaminophen causes liver damage through a toxic byproduct called NAPQI, which forms when the liver’s normal processing pathways become overwhelmed. At recommended doses, your body neutralizes NAPQI almost instantly. But when too much acetaminophen floods the system, NAPQI accumulates and begins destroying liver cells from the inside out, starting with their mitochondria. Understanding how this happens, who is most vulnerable, and what treatments exist can genuinely be the difference between a scare and a catastrophe.

How the Liver Normally Handles Acetaminophen

When you swallow a standard dose of acetaminophen, your liver breaks it down through two main chemical pathways: sulfation and glucuronidation. These are the workhorses. They attach small molecules to the drug, making it water-soluble so your kidneys can flush it out. Together, these two pathways handle the vast majority of the dose without producing anything dangerous. In children, sulfation does a larger share of the work than glucuronidation, a ratio that gradually shifts as a person matures into adulthood.¹

A small fraction of the dose, typically around 5 to 10 percent, takes a different route. Certain liver enzymes in the cytochrome P450 family oxidize it into a highly reactive compound called N-acetyl-p-benzoquinone imine, or NAPQI. At normal doses, this is not a problem. Your liver keeps a reserve of a molecule called glutathione, which grabs NAPQI and neutralizes it almost as fast as it forms. The neutralized product is harmless and gets excreted. At therapeutic doses, the system runs smoothly because glutathione supplies are more than sufficient to handle the small amount of NAPQI produced.

Where Things Go Wrong

In an overdose, the safe pathways (sulfation and glucuronidation) become saturated. They can only process so much drug per hour. The excess acetaminophen gets shunted into the cytochrome P450 pathway, generating far more NAPQI than the liver’s glutathione can handle. Once glutathione stores are depleted, free NAPQI starts binding directly to proteins inside liver cells.²

The damage centers on the mitochondria, the energy-producing structures inside each cell. NAPQI forms protein adducts there, which trigger a cascade of oxidative stress and mitochondrial dysfunction. The cells cannot maintain their energy supply, lose their structural integrity, and die through necrosis, a form of cell death that spills cellular contents into the surrounding tissue and provokes inflammation. This necrosis tends to concentrate in a specific zone of the liver lobule (the centrilobular region), which is where the P450 enzymes are most active and where NAPQI production is highest.²

Which specific P450 enzyme is most responsible for making NAPQI in humans has been debated. One study using human liver tissue concluded that CYP3A4 is the dominant enzyme catalyzing the reaction.³ However, another study in living human subjects found that CYP2E1 accounted for NAPQI formation, with the contribution of other P450 enzymes appearing negligible.⁴ The practical takeaway is the same either way: anything that revs up these enzymes or depletes glutathione shifts the balance toward toxicity.

Who Is at Higher Risk

Several factors can lower the threshold at which acetaminophen becomes dangerous, either by increasing NAPQI production or by reducing the glutathione available to neutralize it.

Chronic Alcohol Use

The relationship between alcohol and acetaminophen toxicity is more nuanced than most people realize. Chronic heavy drinking upregulates CYP2E1, the enzyme that converts acetaminophen to NAPQI. That means a person who drinks regularly and then takes acetaminophen, even at doses close to the recommended maximum, may produce more NAPQI than a non-drinker would. Mathematical modeling confirms that chronic alcohol use increases susceptibility to acetaminophen toxicity, and the risk goes up with higher alcohol intake.⁵

Here is the counterintuitive part: if you drink alcohol and take acetaminophen at roughly the same time, the alcohol actually competes for the same enzyme, temporarily blocking NAPQI formation. Acute alcohol ingestion alongside an acetaminophen overdose can paradoxically reduce liver injury compared to the same overdose without alcohol. The danger for chronic drinkers comes when they stop drinking for a day or more and then take acetaminophen. At that point, their CYP enzymes are still ramped up from chronic exposure, but alcohol is no longer around to compete for the enzyme’s attention, so NAPQI production surges.⁵

Malnutrition and Fasting

Glutathione is made from amino acids, particularly cysteine. People who are malnourished or have eating disorders often have reduced glutathione stores because the building blocks are in short supply. Animal studies have shown dramatic increases in liver injury markers when acetaminophen is given after periods of food restriction, and human data from children with anorexia nervosa shows substantially lower glutathione levels compared to healthy children.⁶

That said, one review found that aging alone and short-term acute fasting are not convincingly associated with increased risk of acetaminophen-related liver injury through glutathione depletion in otherwise healthy people.⁷ The distinction matters: chronic malnutrition is a genuine risk factor, but skipping lunch before taking a couple of acetaminophen tablets is not likely to cause harm in an otherwise healthy person.

Accidental Double-Dosing

One of the most common routes to unintentional overdose is taking two products that both contain acetaminophen without realizing it. Acetaminophen appears in hundreds of over-the-counter medications, from cold remedies and sleep aids to combination pain relievers. In one study, nearly half of adults demonstrated they would unintentionally overdose by using two acetaminophen-containing products at the same time.⁸ This “double-dipping” is a far more common scenario than deliberate massive overdose, and it can creep up over days as someone treats a cold or flu with multiple remedies.

The Antidote and How It Works

N-acetylcysteine, commonly known as NAC, has been the standard treatment for acetaminophen poisoning since the 1970s. It is remarkably effective when given early. Its primary mechanism is straightforward: NAC serves as a precursor for glutathione synthesis, replenishing the depleted stores so the liver can resume detoxifying NAPQI. In animal studies, NAC increased glutathione production roughly fivefold during the critical early window of poisoning.⁹

NAC works through multiple channels, not just glutathione replenishment. In the later stages of liver injury, when glutathione alone is no longer sufficient, NAC appears to improve liver blood flow, modify inflammatory signaling, and act as a free-radical scavenger.¹⁰ This is why NAC still provides some benefit even when given late, well past the point where glutathione depletion is the main driver of injury.

Today, NAC is most commonly given intravenously in hospitals. Doctors use a treatment nomogram, most recently updated in 2023, to decide whether a patient needs NAC based on the time since ingestion and the measured blood level of acetaminophen. The current version stratifies patients into high-risk and standard-risk groups, with blood acetaminophen above a defined threshold at four hours after ingestion triggering treatment.¹¹

What Defines an Overdose

A 2023 consensus statement from toxicologists in the US and Canada makes an important clinical distinction. An acute ingestion is any amount taken within a period of less than 24 hours, regardless of whether it was all at once or spread out. A repeated supratherapeutic ingestion, by contrast, occurs over a period longer than 24 hours, such as someone taking too much every 4 to 6 hours for several days. The management approach differs between these two patterns.¹² For acute ingestions, the treatment nomogram guides the decision. For repeated supratherapeutic ingestions, clinicians rely more on the patient’s symptoms and lab values at the time they arrive, because the nomogram was not designed for this staggered-dose pattern.

This distinction is practically important because the staggered pattern is common in accidental overdoses. Someone with a bad toothache who takes “just a couple extra” every few hours for two or three days may present to the emergency room feeling nauseated, not realizing they have been slowly overwhelming their liver’s capacity. These patients sometimes arrive later and sicker than people who take a single large dose and seek help promptly.

Fomepizole as an Emerging Treatment

NAC is excellent but not perfect. In very large overdoses or when treatment is delayed, some patients still develop severe liver injury despite receiving NAC. Researchers have been exploring fomepizole (also known as 4-methylpyrazole) as a potential add-on therapy. Fomepizole is already approved for treating methanol and ethylene glycol poisoning, where it works by blocking the enzyme that converts those substances into toxic metabolites. The idea with acetaminophen is similar: block the CYP enzyme that creates NAPQI in the first place.

Early rat studies showed that fomepizole given four hours after a toxic dose of acetaminophen significantly reduced liver enzyme elevations and hepatic necrosis.¹³ More recently, a randomized crossover study in human volunteers found that fomepizole given two hours after acetaminophen reduced NAPQI formation by roughly 60 to 70 percent.¹⁴ The idea is not to replace NAC but to use fomepizole alongside it in severe cases, attacking the problem from both ends: reducing NAPQI production while simultaneously boosting the liver’s ability to clear whatever NAPQI still forms.

How the Liver Recovers

The liver has a remarkable capacity for self-repair. After acetaminophen injury, surviving liver cells begin to proliferate to replace the dead tissue. This regeneration ramps up in proportion to how severe the injury was, and in most cases of acetaminophen overdose, it leads to spontaneous recovery without long-term damage.¹⁵ Coordination between different cell types in the liver drives this process. Immune cells, stellate cells, and endothelial cells all release signals that push the remaining hepatocytes to divide.

The catch is that very severe overdoses can overwhelm the regenerative machinery. When injury is extensive enough, the signaling pathways that normally trigger cell division become disrupted, and liver regeneration stalls. At that point, the injury keeps progressing unchecked, and the patient may develop acute liver failure. Research into what makes regeneration succeed or fail is active, with recent studies identifying specific molecular pathways. For instance, a transcription factor called HNF4α appears to be critical for both glutathione replenishment during recovery and successful hepatocyte proliferation after acetaminophen injury.¹⁶

When the Liver Cannot Recover

In a small percentage of severe cases, the liver fails completely. Acetaminophen is the leading cause of acute liver failure in the United States, and when it reaches that stage, liver transplantation may be the only option. Deciding which patients need a transplant versus which will recover on their own is one of the hardest judgment calls in critical care. Several scoring systems help clinicians make this determination. The King’s College Hospital criteria have been widely used for decades and are highly specific, meaning that if a patient meets those criteria, the chance of spontaneous survival is low. However, those criteria have relatively poor sensitivity, missing roughly half of patients who ultimately do not survive without a transplant.¹⁷

Newer dynamic models attempt to improve on static criteria by tracking how a patient’s labs change over time. A model from King’s College Hospital’s liver intensive care unit incorporates changing lactate and blood-clotting values alongside admission data such as kidney function and blood acidity, and has shown improved ability to distinguish survivors from non-survivors across multiple transplant centers.¹⁸ The shift from one-time assessments to dynamic monitoring reflects a broader recognition that the trajectory of organ function matters more than any single snapshot.

Diagnosing Acetaminophen Toxicity When the Story Is Unclear

Not everyone who arrives with acute liver failure can provide a clear history. Some patients are confused or unconscious. Others may not realize they took acetaminophen, especially if it was a component of a combination product. In these ambiguous cases, measuring blood levels of the drug itself is not always helpful, because acetaminophen may have already been cleared from the bloodstream even though liver damage is ongoing.

A more reliable approach involves measuring acetaminophen-protein adducts in the blood. These are the byproducts of NAPQI binding to proteins, and they persist in the circulation longer than free acetaminophen does. In patients with confirmed acetaminophen toxicity, adduct levels were consistently elevated, while patients with liver failure from other causes had essentially undetectable levels. In one study, the assay achieved perfect sensitivity and specificity in distinguishing acetaminophen-related liver failure from other causes.¹⁹ While this test is not yet universally available, it represents a significant diagnostic advance for cases where the clinical history alone cannot confirm the cause.

Pack Size Restrictions and Their Mixed Results

In 1998, the United Kingdom introduced legislation limiting the number of acetaminophen (paracetamol) tablets that could be sold in a single package. The logic was simple: if people could not easily obtain large quantities, impulsive overdoses would involve fewer tablets and cause less harm. A review of seventeen studies examining the impact of this legislation found a mixed picture. Several studies reported reductions in mortality rates, liver unit admissions, and liver transplantation rates. The severity of overdoses appeared to decrease, with fewer tablets ingested per episode and lower blood levels on arrival. But other studies found no significant change or even initial decreases that reversed over time.²⁰

Complicating the interpretation, some of the improvements in outcomes appeared to have begun before the legislation took effect, suggesting that other factors, including better treatment with NAC and greater public awareness, may have contributed.²¹ The United States has not adopted similar pack size limits but instead relies on labeling requirements and the 2011 FDA request that manufacturers limit the amount of acetaminophen in prescription combination products. Whether any of these regulatory strategies meaningfully reduces harm remains an open question, though the overall trend in overdose severity in the UK does seem to have improved since the late 1990s.

Acetaminophen in Children

Children process acetaminophen differently from adults. In neonates, sulfation is the dominant metabolic pathway, while glucuronidation plays a smaller role.²² As children grow, this balance gradually shifts toward the adult pattern. The P450 oxidation pathway that generates NAPQI is also less active in young children, which may partly explain why serious acetaminophen toxicity, while certainly possible in children, tends to occur at relatively higher doses on a per-weight basis than in adults. Dosing for children is based on body weight, and caregivers should use the measuring device that comes with the product rather than a kitchen spoon, which is a consistent source of dosing errors. Liquid formulations come in different concentrations, and confusing infant drops with children’s suspension can lead to substantial overdoses.

Repeated supratherapeutic dosing is a particular hazard in pediatric settings. A feverish child being treated by rotating caregivers, each of whom gives a dose without knowing the last one was given an hour ago, can accumulate a dangerous amount over a day or two. Unlike a single large ingestion in an adult, these staggered pediatric overdoses often present late, when the liver is already injured, making treatment more complicated.